CSTL - Castle Biosciences Inc Stock Price, Fair Value and News

23.64USD-0.16 (-0.67%)Delayed as of 08 May 2024, 02:00 pm ET

Market Summary

USD23.64-0.16

Delayedas of 08 May 2024, 02:00 pm

-0.67%

CSTL Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)
Losses in recent quarter

CSTL Stock Price

View Fullscreen

CSTL RSI Chart

CSTL Valuation

Market Cap

657.1M

Price/Earnings (Trailing)

-21.34

Price/Sales (Trailing)

2.62

Price/Free Cashflow

-101.76

CSTL Price/Sales (Trailing)

CSTL Profitability

Operating Margin

80.58%

Return on Equity

-7.65%

Return on Assets

-6.72%

Free Cashflow Yield

-0.98%

CSTL Fundamentals

CSTL Revenue

Revenue (TTM)

250.7M

Rev. Growth (Yr)

73.59%

Rev. Growth (Qtr)

10.37%

CSTL Earnings

Earnings (TTM)

-30.8M

Earnings Growth (Yr)

91.32%

Earnings Growth (Qtr)

1.78%

Breaking Down CSTL Revenue

52 Week Range

23.98

(Low)(High)

Last 7 days

12.7%

Last 30 days

14.2%

Last 90 days

1.3%

Trailing 12 Months

5.0%

How does CSTL drawdown profile look like?

CSTL Financial Health

Current Ratio

9.25

Debt/Equity

0.02

Debt/Cashflow

1.3

CSTL Investor Care

Shares Dilution (1Y)

3.43%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	250.7M	0	0	0
2023	152.2M	167.5M	192.0M	219.8M
2022	98.1M	110.2M	123.7M	137.0M
2021	68.0M	78.1M	86.3M	94.1M
2020	60.6M	62.5M	63.0M	62.6M
2019	27.8M	34.6M	45.7M	51.9M
2018	0	0	0	22.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Castle Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 23, 2024	maetzold derek j	sold	-4,323	20.109	-215	pres. & chief exec. officer
Apr 23, 2024	maetzold derek j	sold	-1,387	20.109	-69.00	pres. & chief exec. officer
Apr 23, 2024	maetzold derek j	sold	-1,367	20.109	-68.00	pres. & chief exec. officer
Apr 23, 2024	maetzold derek j	sold	-8,465	20.109	-421	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-6,450	20.35	-317	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-6,471	20.35	-318	pres. & chief exec. officer
Apr 12, 2024	maetzold derek j	sold	-20,288	20.35	-997	pres. & chief exec. officer

Which funds bought or sold CSTL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Parallel Advisors, LLC	reduced	-1.11	8,727	590,696	0.02%
May 06, 2024	NEW YORK LIFE INVESTMENT MANAGEMENT LLC	new	-	365,829	365,829	-%
May 06, 2024	BANQUE PICTET & CIE SA	reduced	-8.64	-245,475	3,696,410	0.04%
May 06, 2024	Advisors Capital Management, LLC	added	15.77	496,000	3,126,000	0.06%
May 03, 2024	GSA CAPITAL PARTNERS LLP	added	9.05	124,000	1,162,000	0.09%
May 03, 2024	HUNTINGTON NATIONAL BANK	unchanged	-	-	22.00	-%
May 03, 2024	RiverPark Advisors, LLC	added	362	50,013	63,371	0.05%
May 02, 2024	Daiwa Securities Group Inc.	unchanged	-	-	2,000	-%
May 02, 2024	NISA INVESTMENT ADVISORS, LLC	added	2.5	359	7,265	-%
May 02, 2024	KORNITZER CAPITAL MANAGEMENT INC /KS	unchanged	-	309,438	12,024,700	0.22%

Are Funds Buying or Selling CSTL?

Are funds buying CSTL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CSTL

No. of Funds

Unveiling Castle Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	granahan investment management, llc	8.05%	2,166,471	SC 13G
Feb 13, 2024	principal global investors	5.89%	1,585,639	SC 13G
Feb 13, 2024	vanguard group inc	5.43%	1,461,481	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	8.5%	2,283,199	SC 13G/A
Feb 09, 2023	wasatch advisors inc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	5.29%	1,392,724	SC 13G
Feb 03, 2023	blackrock inc.	8.1%	2,123,688	SC 13G/A
Feb 11, 2022	maetzold derek j	4.0%	1,022,068	SC 13G/A
Feb 10, 2022	wasatch advisors inc	-	0	SC 13G/A

Recent SEC filings of Castle Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 25, 2024	4	Insider Trading
Apr 16, 2024	EFFECT	EFFECT
Apr 16, 2024	4	Insider Trading
Apr 12, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	DEF 14A	DEF 14A
Apr 10, 2024	DEFA14A	DEFA14A
Apr 10, 2024	ARS	ARS
Apr 10, 2024	4	Insider Trading

Peers (Alternatives to Castle Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	184.3B	23.7B	1.86%	4.00%	41.87	7.76	-8.94%	-35.91%
A	41.4B	6.7B	-1.98%	6.66%	33.5	6.15	-2.81%	-6.58%
IDXX	40.0B	3.7B	-6.80%	-0.27%	46.15	10.74	8.57%	23.94%
DGX	15.2B	9.3B	4.84%	1.65%	17.98	1.64	-3.29%	6.68%
MEDP	12.5B	2.0B	0.34%	91.91%	39.87	6.35	25.57%	21.62%
CRL	12.1B	4.1B	-6.65%	24.43%	25.56	2.94	3.86%	-2.39%
NTRA	11.7B	1.1B	0.49%	83.09%	-27	10.84	31.99%	20.63%
EXAS	11.1B	2.5B	-12.56%	-10.42%	-54.61	4.46	19.93%	67.26%
MID-CAP
NEOG	2.7B	929.2M	-13.59%	-27.74%	1.7K	2.89	28.93%	111.61%
GH	2.3B	563.9M	6.75%	-20.02%	-4.78	4.06	25.45%	26.76%
SMALL-CAP
CDNA	542.6M	280.3M	8.83%	27.65%	-2.85	1.94	-12.89%	-148.37%
ACRS	95.5M	31.1M	14.29%	-83.81%	-1.24	3.07	0.95%	19.75%
APDN	61.1M	9.0M	833.33%	253.40%	-8.46	6.79	-53.31%	2.21%
AWH	36.4M	9.2M	11.36%	-35.81%	-2.18	3.98	11.85%	44.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Castle Biosciences Inc News

Latest updates

Castle Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	10.4%	73.00	66.00	61.00	50.00	42.00	38.00	37.00	35.00	27.00	25.00	23.00	23.00	23.00	17.00	15.00	13.00	17.00	18.00	15.00	11.00	9.00
Cost Of Revenue	11.8%	14.00	12.00	11.00	11.00	10.00	10.00	9.00	8.00	6.00	5.00	5.00	4.00	3.00	-	2.00	2.00	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	15.00	13.00	11.00	15.00	16.00	13.00	9.00	7.00
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	24.00	-	-	-	14.00	13.00	9.00	8.00	7.00
S&GA Expenses	10.0%	48.00	44.00	45.00	45.00	47.00	38.00	37.00	37.00	30.00	25.00	23.00	21.00	18.00	15.00	12.00	10.00	11.00	10.00	7.00	7.00	6.00
R&D Expenses	6.3%	14.00	13.00	13.00	13.00	14.00	11.00	11.00	12.00	11.00	9.00	8.00	7.00	6.00	5.00	3.00	3.00	3.00	3.00	2.00	1.00	1.00
Interest Expenses	600.0%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	0.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00
Income Taxes	15.4%	0.00	0.00	0.00	0.00	0.00	0.00	-	-1.96	0.00	-1.77	-	0.00	-	0.00	-	-	-	0.00	-	-	-
Net Income	1.8%	-2.53	-2.58	-6.90	-18.78	-29.20	-20.62	-20.25	-1.65	-24.62	-6.43	-11.79	-8.79	-4.28	-4.89	-4.59	-1.38	1.00	2.00	6.00	-1.27	-1.36
Net Income Margin	53.0%	-0.12*	-0.26*	-0.39*	-0.53*	-0.47*	-0.49*	-0.43*	-0.40*	-0.53*	-0.33*	-0.34*	-0.29*	-	-	-	-	-	-	-	-	-
Free Cashflow	-208.1%	-15.99	15.00	3.00	-7.82	-28.78	-7.79	-7.26	-10.41	-21.83	-3.67	-7.06	-7.35	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Assets	1.1%	459	453	436	425	427	447	458	458	444	463	434	436	437	439	210	202	120	120	113	33.00	22.00
Current Assets	0.0%	296	296	280	269	271	292	299	305	336	354	390	392	427	430	201	196	117	117	110	29.00	18.00
Cash Equivalents	-16.0%	83.00	99.00	91.00	96.00	115	123	134	273	309	330	363	368	407	410	183	180	99.00	99.00	94.00	17.00	4.00
Inventory	-3.7%	8.00	8.00	6.00	6.00	5.00	4.00	4.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00
Net PPE	-	-	-	22.00	21.00	18.00	14.00	13.00	11.00	9.00	10.00	9.00	8.00	8.00	7.00	7.00	5.00	3.00	2.00	2.00	2.00	2.00
Liabilities	-9.7%	56.00	62.00	50.00	47.00	42.00	48.00	46.00	37.00	47.00	51.00	22.00	20.00	19.00	24.00	44.00	44.00	32.00	35.00	31.00	37.00	32.00
Current Liabilities	-33.0%	32.00	48.00	36.00	34.00	30.00	36.00	32.00	28.00	40.00	25.00	21.00	19.00	18.00	21.00	30.00	28.00	15.00	15.00	9.00	12.00	7.00
Short Term Borrowings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.00	-
Long Term Debt	-	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	15.00	17.00	19.00	22.00	24.00	25.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	10.00	8.00	6.00	3.00	1.00	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12.00	15.00	17.00	19.00	22.00	24.00	25.00
Shareholder's Equity	2.9%	402	391	386	379	385	399	411	422	397	412	412	416	419	416	167	158	88.00	85.00	82.00	-	-
Retained Earnings	-1.2%	-220	-218	-215	-208	-190	-160	-140	-120	-118	-93.77	-87.36	-75.57	-66.78	-62.50	-57.61	-53.02	-51.64	-52.21	-54.30	-60.12	-57.49
Additional Paid-In Capital	2.3%	623	609	602	588	575	560	552	542	516	505	499	491	485	478	224	211	140	137	137	10.00	1.00
Shares Outstanding	0.6%	28.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	25.00	25.00	25.00	25.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	311	-	-	-	472	-	-	-	1,500	-	-	-	519	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-136.8%	-6,835	18,587	5,012	-3,786	-25,439	-6,000	-5,224	-9,001	-21,430	-2,781	-6,133	-6,438	-3,631	-430	-2,955	13,501	-251	4,493	752	482	1,288
Share Based Compensation	7.4%	12,675	11,802	13,043	12,849	13,525	9,923	9,196	8,783	8,419	6,851	5,210	4,766	4,913	2,961	2,118	1,653	1,577	713	229	139	168
Cashflow From Investing	-156.8%	-19,701	-7,672	-9,708	-15,387	16,584	-4,482	-134,150	-27,511	-402	-30,889	-923	-34,095	-750	-588	-1,904	-1,756	-500	-347	-166	-180	-244
Cashflow From Financing	422.8%	10,644	-3,297	45.00	226	728	-750	388	661	1,216	126	1,894	1,891	1,510	227,820	8,150	69,361	559	224	76,421	936	10,707

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CSTL Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
NET REVENUES	$ 72,974	$ 42,037
OPERATING EXPENSES
Cost of sales (exclusive of amortization of acquired intangible assets)	13,894	10,182
Research and development	13,809	14,393
Selling, general and administrative	48,495	46,762
Amortization of acquired intangible assets	2,247	2,222
Total operating expenses, net	78,445	73,559
Operating loss	(5,471)	(31,522)
Interest income	2,996	2,336
Interest expense	(14)	(4)
Loss before income taxes	(2,489)	(29,190)
Income tax expense	45	14
Net loss	$ (2,534)	$ (29,204)
Loss per share, basic (in dollars per share)	$ (0.09)	$ (1.10)
Loss per share, diluted (in dollars per share)	$ (0.09)	$ (1.10)
Weighted-average shares outstanding, basic (in shares)	27,485	26,607
Weighted-average shares outstanding, diluted (in shares)	27,485	26,607

CSTL Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 82,949	$ 98,841
Marketable investment securities	156,264	144,258
Accounts receivable, net	42,699	38,302
Inventory	7,645	7,942
Prepaid expenses and other current assets	6,221	6,292
Total current assets	295,778	295,635
Long-term accounts receivable, net	1,056	1,191
Property and equipment, net	32,904	25,433
Operating lease assets	11,961	12,306
Goodwill and other intangible assets, net	115,088	117,335
Other assets – long-term	1,720	1,440
Total assets	458,507	453,340
Current Liabilities
Accounts payable	9,318	10,268
Accrued compensation	14,708	28,945
Operating lease liabilities	1,189	1,137
Other accrued and current liabilities	6,744	7,317
Total current liabilities	31,959	47,667
Long-term debt	10,000	0
Noncurrent operating lease liabilities	13,864	14,173
Deferred tax liability	206	206
Other liabilities	16	25
Total liabilities	56,045	62,071
Commitments and Contingencies (Note 11)
Stockholders’ Equity
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 27,585,669 and 27,410,532 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	28	27
Additional paid-in capital	623,450	609,477
Accumulated deficit	(220,905)	(218,371)
Accumulated other comprehensive (loss) income	(111)	136
Total stockholders’ equity	402,462	391,269
Total liabilities and stockholders’ equity	$ 458,507	$ 453,340

About Castle Biosciences Inc

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

CEO	Mr. Derek J. Maetzold
WEBSITE	https://castlebiosciences.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	582

Castle Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Castle Biosciences Inc? What does CSTL stand for in stocks?

CSTL is the stock ticker symbol of Castle Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Castle Biosciences Inc (CSTL)?

As of Tue May 07 2024, market cap of Castle Biosciences Inc is 657.05 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CSTL stock?

You can check CSTL's fair value in chart for subscribers.

What is the fair value of CSTL stock?

You can check CSTL's fair value in chart for subscribers. The fair value of Castle Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Castle Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CSTL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Castle Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CSTL is over valued or under valued. Whether Castle Biosciences Inc is cheap or expensive depends on the assumptions which impact Castle Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CSTL.

What is Castle Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, CSTL's PE ratio (Price to Earnings) is -21.34 and Price to Sales (PS) ratio is 2.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CSTL PE ratio will change depending on the future growth rate expectations of investors.